Medimmune Limited

Other

Astrazeneca Ab

Srinath Kasturirangan

Changshou Gao

Godfrey Rainey

Cuihua Gao

Nicole Kallewaard-LeLay

Qing Zhu

Yariv Mazor

Scott A Hammond

Claire Louise Dobson

Ronald Herbst

Darren Schofield

Stacey Drabic

Michelle Morrow

Michael Oberst

Brian Lobo

Prakash Manikwar

Simon Dovedi

Jonathan Seaman

Gianluca Carlesso

Kristen Pollizzi

Melissa Marie Damschroder

John H Li

Andy Q Yuan

Nazzareno Dimasi

Qun Du

Ryan Fleming

Steven Roy Coats

Binyam Bezabeh

Dorin Toader

Lakshmaiah Gingipalli

Fengjiang Wang

Andrew Grier Buchanan

Chunning Yang

Frank Irvine Comer

Nicole Kallewaard-Lelay

Godfrey Jonah Rainey

Andy Qingan Yuan

The present disclosure relates to antibody molecules that bind epidermal growth factor receptor (EGFR) and/or c-Met and conjugates containing these antibody molecules. The antibody molecules and conjugates find application in the treatment of cancer, for example.

Antibody molecules and conjugates

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

Bispecific binding proteins and uses thereof

Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.

Neutralizing anti-influenza binding molecules and uses thereof

The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.

Bispecific HER2 antibodies

Growing community of inventors

Gaithersburg, MD, United States of America

Srinath Kasturirangan